Cuba invited to US conference

A Cuban pharmacologist and genetics expert was a speaker at a Puerto Rico biotech conference co-organized with the FDA

Written byBrendan Borrell
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
A notable face set foot on the US Food and Drug Administration waterfront campus in San Juan, Puerto Rico Thursday (May 13) morning. Diadelis Remírez, a molecular pharmacologist and genetics expert with Cuba's drug regulator, Centro Para El Control Estatal de la Calidad de Los Medicamentos, was an invited speaker at the 1st linkurl:Latin American Pharmacogenomics and Personalized Medicine Congress.;http://induniv.org/pharmacogenomic/
Diadelis Remírez
Image: Brendan Borrell
The congress, organized by the FDA and INDUNIV, a Puerto Rican non-profit research consortium made up of pharmaceutical companies, government agencies, and academics, featured speakers from across Latin America discussing the challenges of working with their racially mixed populations. "It's important to have everyone here," said Ivan Lugo Montes, executive director of linkurl:INDUNIV,;http://www.induniv.org/ which paid for Remírez's travel.And Remírez, most everyone agreed, was a beam of sunshine, playing down the four hours she spent stuck in the Miami airport after she missed her plane because of a lengthy interrogation by immigration agents. At least, she made it. In 2009, US scientists tried to set up a pharmacogenomics workshop with her in Cuba, which has been praised for its recent advances in biotech, but were denied permission. "This is very important for me and my country so we can improve our drugs," she said. On Friday, she will be presenting her talk, "Pharmacogenetic studies: results and regulatory perspectives in Cuba.""Public health is public health no matter where you are," said one FDA official who did not wish to be named.
**__Related stories:__***linkurl:FDA floats new conflict policy;http://www.the-scientist.com/blog/display/57373/
[22nd April 2010]*linkurl:More regulatory science: FDA chief;http://www.the-scientist.com/blog/display/55984/
[17th September 2009]*linkurl:The next FDA commissioner is...;http://www.the-scientist.com/news/display/55452/
[24th February 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies